# US 2021/0268037 A1 · Anaerostipes hadrus for use in promoting health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0268037 A1
- Document ID: US20210268037A1
- Status: Published application
- Kind: A1
- Application number: 17/255,126
- Filed: 2019-06-25
- Published: 2021-09-02
- Earliest claimed: 2018-06-25
- Assignees: Second Genome, Inc.; University College Cork, National University of Ireland
- Applicants: Second Genome, Inc.; University College Cork - National University of Ireland
- Inventors: Shoko Kawana; Todd Z. DeSantis; Marcus J. Claesson; Feargal J. Ryan
- Web page: https://patentgrep.com/patent/US20210268037A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/689: for bacteria
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat a gastrointestinal disease or disorder. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Anaerostipes hadrus and their uses in treating intestinal diseases or disorders.

## Claims

### Claim 1

A method for treating a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a bacterium, wherein the bacterium has a 16S RNA gene that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:8.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the bacterium has a 16S RNA gene that is at least 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO:8.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the bacterium administered to the subject is viable.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the subject has been diagnosed with a gastrointestinal disorder.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the gastrointestinal disorder is selected from the group consisting of ulcerative colitis, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, and celiac disease.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the therapeutically effective amount of the bacterium comprises about 1×107 to 1×1012 colony forming units (CFU) of the bacterium.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the bacterium is A. Hadrus.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the method comprises administering the composition to the subject once, twice or three times per day over a time period of about 1-52 weeks.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the weight loss of the subject after administration of the composition is less than that of a comparable patient who did not receive administration of the composition.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the weight loss of the subject after administration of the composition is about 5 lbs, 10 lbs, 15 lbs, 20 lbs, 25 lbs or 30 lbs less than that of a comparable patient who did not receive administration of the composition.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the weight loss of the subject is measured at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months after the first administration of the composition.

### Claim 12

A method for maintaining or improving overall fitness or health of a patient, said method comprising:
administering to the patient a therapeutic composition comprising:
i. an effective amount of a composition comprising a bacterium, wherein the bacterium has a 16S RNA gene that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:8; and
ii. a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The method of claim 12, wherein the overall fitness or health of the patient after administration of the composition is greater than that of a comparable patient who did not receive administration of the composition.
